ABG Acquisition Corp. I Stock: price and insider trades · United States · SEC (Form 4)

About ABG Acquisition Corp. I

ABG Acquisition Corp. I is a U.S.-listed special purpose acquisition company (SPAC) that was originally designed to pursue a merger, share exchange, asset acquisition, or similar business combination with a private operating company. According to its SEC filings, the company was formed as a blank-check vehicle with an initial focus on the healthcare sector, which is why it is best classified under Health & Pharma. Its filings and public disclosures tie it to New York, a major U.S. capital-markets hub. The relevant market context is the Nasdaq, where the company was listed as ABGI before its wind-down. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1833764/000119312522085204/d320643d10k.htm?utm_source=openai)) Historically, ABG Acquisition Corp. I came to market during the 2020–2021 SPAC boom. Press coverage at the time described it as an Ally Bridge Group-sponsored blank-check company targeting healthcare and filing for an IPO of roughly $120 million. The sponsor, ABG Acquisition Holdings I LLC, underpinned the transaction and the company’s original investment thesis. As with any SPAC, the business model was not to manufacture products or deliver end-market services directly; rather, the company’s core activity was to raise capital, identify a target, negotiate a deal, and bring that target to the public market through a de-SPAC transaction. ([nasdaq.com](https://www.nasdaq.com/articles/ally-bridge-groups-spac-abg-acquisition-i-files-for-a-%24120-million-ipo-2021-02-01?utm_source=openai)) From a competitive standpoint, ABG Acquisition Corp. I operated in a crowded universe of acquisition vehicles where differentiation depends on sponsor reputation, access to proprietary deal flow, sector specialization, and execution speed. Its healthcare mandate was meaningful because healthcare SPACs can attract businesses with recurring revenue, structural growth, and long-duration innovation pipelines in areas such as biotech, medtech, healthcare services, and life sciences tools. That said, the company’s success ultimately depended on closing a transaction within the time allowed by its governing documents. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1833764/000119312522085204/d320643d10k.htm?utm_source=openai)) The most important recent development is that the company did not complete an initial business combination. In February 2023, it announced that it would redeem its publicly held Class A ordinary shares, cease operating except for winding up, and expected its securities to stop trading on Nasdaq as the company moved toward dissolution. For investors following SEC Form 4 insider activity, that context is essential: ABG Acquisition Corp. I is no longer functioning as a live growth story, but as a SPAC that entered liquidation after failing to consummate a deal. ([nasdaq.com](https://www.nasdaq.com/press-release/abg-acquisition-corp.-i-will-redeem-its-publicly-held-class-a-ordinary-shares-2023-02?utm_source=openai))